India weighs mandatory red-label warnings on cough syrups for children under 4
India’s drug regulator is considering prominent red warnings and child-focused imagery on cough-syrup packs to discourage use among children under four, potentially extending restrictions on chlorpheniramine-phenylephrine combinations.
What happened
retail-company · India’s drug regulator is considering mandatory red warnings and school-age imagery on cough-syrup labels to discourage use in children under
Key facts
- Children below 4 years
- Children below 2 years
- October 2025
- April 2026
- August 22
What changed
India’s drug regulator is considering mandatory red warnings and school-age imagery on cough-syrup labels to discourage use in children under four, extending recent restrictions on chlorpheniramine-phenylephrine combinations.
Why this matters
Prepare for potential paediatric cough-syrup pack redesigns, retailer education, and tighter age-gating of sales if India mandates prominent under-four warnings.
What to watch
- Publication of CDSCO or Health Ministry draft notification, consultation paper, or final labeling standard.
- Explicit inclusion of chlorpheniramine-phenylephrine combinations, other antihistamine-decongestant products, or fixed-dose combinations.
- Mandated warning language, font/color requirements, child imagery specifications, and packaging-transition deadlines.
- State drug-controller enforcement notices, pharmacy inspection activity, product recalls, or license suspensions.
- Major manufacturers announcing reformulations, label revisions, shipment holds, or discontinuation of paediatric SKUs.